Pooled analysis data showed improvements in glycaemic parameters, body weight and blood pressure with investigational agent empagliflozin in adults with Type 2 Diabetes

Pooled analysis data showed improvements in glycaemic parameters, body weight and blood pressure with investigational agent empagliflozin in adults with Type 2 Diabetes
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news